A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Nigel H. Russell, William Villiers et al.|Blood Advances|2023Cited by 53
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Leukemia|2023Cited by 48
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Charlotte S. Wilhelm-Benartzi et al.|Journal of Clinical Oncology|2024Cited by 40
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Jad Othman et al.|Blood Advances|2023Cited by 29
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Richard Dillon, Jelena Jovanović et al.|The Lancet Haematology|2025Cited by 9